LEKR1_Lekr1 Inhibitors
Leucine, Glutamate, and Lysine Rich 1 (LEK1) is a protein whose specific functions and characteristics remain relatively unexplored within the scientific community. As the name suggests, LEK1 is characterized by an amino acid composition that is rich in leucine, glutamate, and lysine residues. These amino acids are often associated with specific structural features and functions within proteins.
Leucine-rich proteins, for example, frequently participate in forming leucine-rich repeat (LRR) structures, which are involved in protein-protein interactions and are commonly found in proteins with roles in signaling, cell adhesion, and immune responses. Glutamate, an acidic amino acid, is often involved in catalytic sites of enzymes or in mediating protein interactions through salt bridge formations. Lysine, a basic amino acid, is known for its role in protein structure and function due to its ability to be post-translationally modified, such as through acetylation or ubiquitination, which can affect protein stability, localization, and interactions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A, an HDAC inhibitor, could indirectly influence Lekr1 by modifying gene expression and chromatin structure. | ||||||
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
5-Azacytidine may affect Lekr1 indirectly by altering gene expression patterns through DNA methylation changes. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib, by inhibiting the proteasome, could indirectly impact Lekr1 by affecting protein degradation pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, might influence Lekr1 indirectly through cellular growth and proliferation pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, could affect Lekr1 indirectly by modulating signaling pathways involved in cell survival and metabolism. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
Ruxolitinib, a JAK/STAT inhibitor, might have indirect effects on Lekr1 by influencing gene expression and signaling pathways. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
XAV-939, a Wnt/β-catenin pathway inhibitor, may indirectly impact Lekr1 by modulating cell signaling pathways related to development and proliferation. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126, an inhibitor of the MAPK/ERK pathway, could indirectly affect Lekr1 by altering signaling pathways involved in cell differentiation and growth. | ||||||
17-AAG | 75747-14-7 | sc-200641 sc-200641A | 1 mg 5 mg | $66.00 $153.00 | 16 | |
17-AAG, an HSP90 inhibitor, might influence Lekr1 indirectly by affecting protein folding and stability. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Chloroquine, an autophagy inhibitor, could have indirect effects on Lekr1 through its role in cellular degradation processes. | ||||||